上皮SOX9通过促进免疫抑制性肿瘤微环境驱动胃腺癌进展和转移
该研究利用RNA测序、患者来源细胞与模型及功能实验,探讨SOX9在晚期胃腺癌中的作用。SOX9在胃腺癌中高表达并与不良预后相关,敲除SOX9可降低干细胞特性、肿瘤形成和转移,并增强CD8+ T细胞反应。SOX9通过旁分泌白血病抑制因子(LIF)介导M2巨噬细胞重极化和抑制T细胞功能,联合靶向LIF/LIFR与CSF1R具有治疗潜力。
要点
- SOX9是胃腺癌中上调最显著的SOX基因之一,高表达与不良预后相关。
- 敲除SOX9可降低患者来源胃腺癌细胞的干细胞特性、肿瘤形成和转移。
- SOX9通过LIF介导M2巨噬细胞重极化和抑制T细胞功能。
核心结论
- 上皮SOX9通过旁分泌LIF因子抑制CD8+ T细胞反应并改变巨噬细胞功能,在胃腺癌中起关键作用。
- 联合靶向LIF/LIFR和CSF1R在靶向SOX9介导的癌症干性、T细胞免疫抑制和转移方面具有很大潜力,提示针对晚期胃腺癌的新型联合治疗。
研究设计与样本
- 研究使用批量RNA测序/单细胞RNA测序、患者来源细胞与模型以及大量体内外功能研究。
- 在PBMCs或CD45+免疫细胞与SOX9高表达或敲除的肿瘤细胞共培养体系中研究免疫反应,并使用KP-Luc2同基因模型评估联合治疗疗效。
主要发现
- SOX9是胃腺癌中上调最显著的SOX基因之一,在原发和转移组织中高表达并与不良预后相关。
- 在患者来源胃腺癌细胞中敲除SOX9显著降低癌症干性特征、肿瘤形成和转移。
- 与胃腺癌患者的PBMCs/CD45+细胞共培养时,敲除SOX9持续增加CD8+ T细胞反应。
- RNA测序鉴定出白血病抑制因子(LIF)为肿瘤细胞中受SOX9调控的首要分泌分子,LIF在恶性腹水中富集。
- LIF介导SOX9诱导的M2巨噬细胞重极化和抑制T细胞功能。
关键数值与推荐
- SOX9在胃腺癌中高表达并与不良预后相关。
- 敲除SOX9降低癌症干性特征、肿瘤形成和转移,并增加CD8+ T细胞反应。
- LIF是受SOX9调控的首要分泌分子,在恶性腹水中富集,介导M2巨噬细胞重极化和抑制T细胞功能。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Many cancers engage embryonic genes for rapid growth and evading the immune system. SOX9 has been upregulated in many tumours, yet the role of SOX9 in mediating immunosuppressive tumour microenvironment is unclear. Here, we aim to dissect the role of SOX9-mediated cancer stemness attributes and immunosuppressive microenvironment in advanced gastric adenocarcinoma (GAC) for novel therapeutic discoveries. METHODS: Bulk RNAseq/scRNA-seq, patient-derived cells/models and extensive functional studies were used to identify the expression and functions of SOX9 and its target genes in vitro and in vivo. Immune responses were studied in PBMCs or CD45+ immune cells cocultured with tumour cells with SOX9high or knockout and the KP-Luc2 syngeneic models were used for efficacy of combinations. RESULTS: SOX9 is one of the most upregulated SOX genes in GAC and highly expressed in primary and metastatic tissues and associated with poor prognosis. Depletion of SOX9 in patient-derived GAC cells significantly decreased cancer stemness attributes, tumour formation and metastases and consistently increased CD8+ T cell responses when cocultured with PBMCs/CD45+ cells from GAC patients. RNA sequencing identified the leukaemia inhibitory factor (LIF) as the top secreted molecule regulated by SOX9 in tumour cells and was enriched in malignant ascites and mediated SOX9-induced M2 macrophage repolarisation and inhibited T cell function. CONCLUSION: Epithelial SOX9 is critical in suppressing CD8+ T cell responses and modified macrophage function in GAC through the paracrine LIF factor. Cotargeting LIF/LIFR and CSF1R has great potential in targeting SOX9-mediated cancer stemness, T cell immunosuppression and metastases suggesting the novel combination therapy against advanced GAC.
引用
- Fan Y, Li Y, Yao X, et al. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut. 2022. PMID: 36002248. doi:10.1136/gutjnl-2021-326581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。